OLT 202
Alternative Names: OLT-202Latest Information Update: 02 Feb 2024
At a glance
- Originator Central Manchester University Hospitals NHS Foundation Trust; University of Manchester
- Developer Orchard Therapeutics
- Class Gene therapies; Haematopoietic stem cells therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Mucopolysaccharidosis III
Most Recent Events
- 24 Jan 2024 Orchard Therapeutics has been acquired by Kyowa Kirin
- 28 May 2023 No recent reports of development identified for preclinical development in Mucopolysaccharidosis-III in United Kingdom (Parenteral)
- 21 May 2021 OLT 202 is still in preclinical trials for Mucopolysaccharidosis type IIIB in United Kingdom (Orchard Therapeutics pipeline, May 2021)